Intelligent Bio Solutions Secures ISO Recertification Amid FDA Compliance Shift
Event summary
- Intelligent Bio Solutions' Intelligent Fingerprinting Drug Screening business recertified to ISO 13485:2016, effective October 14, 2026.
- Recertification aligns with FDA's updated Quality Management System Regulation (QMSR), which incorporated ISO 13485:2016.
- Company also recertified to ISO 9001:2015, reinforcing quality management systems across international operations.
- Certifications support FDA clearance application for Intelligent Fingerprinting Drug Screening System in the U.S.
The big picture
The recertification comes as the FDA's QMSR update formalizes ISO 13485:2016 as the benchmark for medical device manufacturers. This strategic alignment positions Intelligent Bio Solutions to navigate regulatory hurdles more effectively, particularly as it seeks to expand its drug screening system into the U.S. market. The dual ISO certifications also reinforce the company's credibility in global markets, where stringent quality management standards are non-negotiable.
What we're watching
- Regulatory Alignment
- How the ISO 13485:2016 recertification will accelerate FDA clearance for the Intelligent Fingerprinting Drug Screening System.
- Market Expansion
- Whether the recertification will strengthen Intelligent Bio Solutions' position in highly regulated international markets.
- Operational Efficiency
- The pace at which the company can leverage these certifications to streamline operations and reduce compliance costs.